Effect of interferon alpha and ribavirin treatment on serum levels of transforming growth factor-β1, vascular endothelial growth factor, and basic fibroblast growth factor in patients with chronic hepatitis C

Figure 1 Serum levels of TGF-β1 (ng/mL) in CHC group and control group. The box represents the interquartile range. The whiskers indicate the highest and lowest values. The line across the box indicates the median value.

Figure 2 Serum levels of VEGF (pg/mL) in CHC group and control group. The box represents the interquartile range. The whiskers indicate the highest and lowest values. The line across the box indicates the median value.

Figure 3 Serum levels of bFGF (pg/mL) in CHC group and control group. The box represents the interquartile range. The whiskers indicate the highest and lowest values. The line across the box indicates the median value.

Figure 4 Comparison of TGF-β1 levels (mean and SE) before and after the antiviral therapy of CHC patients depending on treatment efficacy.

Figure 5 Comparison of VEGF levels (mean and SE) before and after the antiviral therapy of CHC patients depending on treatment efficacy.

Figure 6 Comparison of bFGF levels (mean and SE) before and after the antiviral therapy of CHC patients depending on treatment efficacy.